Biopharma | May 08, 2026
Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
Initiative aims to strengthen South-South collaboration and capacity building in biomedical research
NEJM study shows strong protection across strains
Hair care & quick commerce shine
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
The leading cancer hospital urges carrier screening to prevent thalassemia burden
The partnership will focus on diabetes and NCD awareness, rare disease screening, and deployment of mobile medical units
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
